Antineoplaston Therapy in Treating Patients With Primary Liver Cancer
Status:
Terminated
Trial end date:
1999-10-17
Target enrollment:
Participant gender:
Summary
Current therapies for Primary Liver Cancer provide very limited benefit to the patient. The
anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the
treatment of Primary Liver Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with advanced Head and Neck Cancer.